0
Medtech
  • Home
  • Insights
  • APAC ▾
    • Medical Device Manufacturing
    • MedTech
    • Orthopedic
  • Europe ▾
    • In Vitro Diagnostics
    • Medical Device Manufacturing
    • Medical Imaging
    • Medtech
    • Orthopedic
  • Conferences
  • Newsletter
  • Subscribe
  • News
  • Whitepaper
  • About Us
  • Biomechanics
  • Haematology
  • Neurology
  • Orthopedic
  • Drug Delivery Device
  • Manufacturing
  • MedTech
  • Oncology
  • Urology
  • Veterinary
  • Respiratory Devices
  • MedTech Devices Startups
  • Startups
  • Gynaecology
  • Nephrology
  • Medical Device
  • Physiotherapy
  • Dental
  • Surgical
  • Simulation
  • Pediatrics
  • Imaging
  • Chronic Care
  • Nanomedicine
  • Dermatology
  • Endoscopy
  • Ophthalmics
  • Ultrasound
  • Robotics
  • Wound Care
  • Diabetes Care
  • CardioVascular
  • Packaging and Sterilization
  • In Vitro Diagnostics
  • Biomechanics
  • Haematology
  • Neurology
  • Orthopedic
  • Drug Delivery Device
  • Manufacturing
  • MedTech
  •   MORE
      • Oncology
      • Urology
      • Veterinary
      • Respiratory Devices
      • MedTech Devices Startups
      • Startups
      • Gynaecology
      • Nephrology
      • Medical Device
      • Physiotherapy
      • Dental
      • Surgical
      • Simulation
      • Pediatrics
      • Imaging
      • Chronic Care
      • Nanomedicine
      • Dermatology
      • Endoscopy
      • Ophthalmics
      • Ultrasound
      • Robotics
      • Wound Care
      • Diabetes Care
      • CardioVascular
      • Packaging/Sterilization
      • In Vitro Diagnostics
×
#

Medical Tech Outlook Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook

Subscribe

loading

THANK YOU FOR SUBSCRIBING

Editor's Pick(1 - 4 of 8)
left
Formula Five for Biotech IT

Jeffrey Keisling, CIO & SVP, Pfizer [NYSE:PFE]

Movement Analysis Offers Quantification of the Benefit of Orthopaedic Interventions

Erin M. Mannen, Ph.D., Assistant Professor of Orthopaedic Surgery and Director of Translational Orthopaedic Research at the University of Arkansas for Medical Sciences

Emerging Technologies for Offloading of the Diabetic Foot

Brian Lepow, DPM, Assistant Professor of Surgery, Baylor College of Medicine

The Coming Era of High Performance Medicine

Jason Burke, System VP, Enterprise Analytics & Data Sciences, UNC Health Care

The Biotech IT PMO 2.0

Paul Ritchie, Knowledge Strategy Leader, MassMutual

Rendering the Power of Integrated Biotechnology Services

Tim Jackson, VP Technology, Advanced Clinical

Advanced Technology Enables those with Physical Limitations

Jesse Rettele, Faculty, Clinical Instructor, Medical Director, L/CPO, UT Health San Antonio

Digitizing Pharmaceuticals

Ashok Upadhyay, IT Sr. Director, Otsuka Pharmaceutical Development & Commercialization, Inc. (U.S.)

right

Recent Trend and Development in Pharmaceutical Industry

By Richard Hu, Associate Director CMC, Curis

Tweet

Richard Hu, Associate Director CMC, Curis

In our exciting and ever-changing industry, pharmaceutical and biotech companies must continue innovating not only their technologies but also the way they do business. Let’s review the top three trends that are “hot” in the eyes of a formulation scientist.

The first thing that came to mind is the advancement of CRISPR/ Cas9, a gene editing technology developed by Professor Zhang at MIT. Inspired by how living cells disable invading viruses, CRISPR (Clustered Regularly Short Palindromic Repeats) technology utilizes Cas9, a nuclease enzyme, to cut DNA strands at a precise location when the target gene is complexed with a guide-RNA. As a result, scientists can disable certain sequence in that gene and understand the function of that particular sequence. Sequentially, CRISPR also enables scientists to add a desired function to the gene by inserting a pre-fabricated sequence. We all know that genes define who we are as life-forms and individuals. There is no doubt that our genes have a profound effect on our health. While still in its infancy, gene editing certainly has the potential to completely transform not only our industry but our world as well. If something can finally bankrupt our social security, I think gene editing will be it.

For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game. In this new hope, scientists are developing drugs that can stimulate our own immune system to recognize and fight cancerous cells. One such advancement is the chimeric antigen receptor (CAR) T-cell technology, in which a patient’s own immune cells are removed, engineered to have the ability to recognize and attack cancerous cells, then infused back to his/her body to fight cancer. While only approved to treat limited types of cancer and may have severe side effects, the approval of Kymriah® and Yescarta® clearly represents the future of personalized medicine. Another trend worth mentioning in immunotherapy is the advancement of checkpoint inhibitor. These drugs are often highly targeted, highly efficient and have relatively low side effects. In recent years, antibody-based checkpoint inhibitors have dramatically improved the management of cancer. To me, developing small molecule version of such inhibitors, which are orally available and going to be much cheaper, is even more exciting.

"For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game. "

In the foreseeable future, biopharmaceutical companies, regardless of their sizes, will continue to utilize R&D outsourcing to access innovations and expertise. According to Visiongain, the global drug discovery outsourcing market is expected to exceed $40 billion by 2026. Meanwhile, the tide of outsourcing model is certainly shifting, especially at early stage. R&D work is coming back to the States, while some companies start to run clinical trials in developing countries, often-times looking for treatment-naïve patients. I also sense a strong focus from pharmaceutical companies on partnering with academia. In the past few years, several major pharma companies moved their R&D headquarters into the most congested neighborhoods in Boston, with the intention to put their folks into the proximity of Harvard and MIT. But for God’s sake, put them in the suburb and take a subway to the “Inspiration” when needed. Haven’t they checked out the Boston morning traffic in last twenty years?

Read Also

The Biotech IT PMO 2.0

The Biotech IT PMO 2.0

Paul Ritchie, Knowledge Strategy Leader, MassMutual
Rendering the Power of Integrated Biotechnology Services

Rendering the Power of Integrated Biotechnology Services

Tim Jackson, VP Technology, Advanced Clinical
Advanced Technology Enables those with Physical Limitations

Advanced Technology Enables those with Physical Limitations

Jesse Rettele, Faculty, Clinical Instructor, Medical Director, L/CPO, UT Health San Antonio
Digitizing Pharmaceuticals

Digitizing Pharmaceuticals

Ashok Upadhyay, IT Sr. Director, Otsuka Pharmaceutical Development & Commercialization, Inc. (U.S.)

Weekly Brief

loading
Top 10 Biomechanics Solution Companies - 2019
ON THE DECK

Biomechanics 2019

Top Vendors

Biomechanics 2018

Top Vendors

Previous Next

Featured Vendors

  • PT Genie: Transforming the Realm of Physical Therapy
    PT Genie: Transforming the Realm of Physical Therapy
  • Ermi: Non-Operative Treatment for Severe Motion Loss
    Ermi: Non-Operative Treatment for Severe Motion Loss
  • Intellirod Spine: Sensing Systems for Spine Surgeons and their Patients
    Intellirod Spine: Sensing Systems for Spine Surgeons and their Patients
  • FX Shoulder USA: The Shoulder Arthroplasty Specialist
    FX Shoulder USA: The Shoulder Arthroplasty Specialist
Copyright © 2019 Medical Tech Outlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy.
follow on linkedin follow on twitter
This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

biomechanics.medicaltechoutlook.com/cxoinsight/recent-trend-and-development-in-pharmaceutical-industry-nwid-405.html?utm_source=google&utm_campaign=medicaltechoutlook_topslider